In line with the National Comprehensive Cancer Network (NCCN) guidelines for breast cancer treatment, a consensus was achieved by the panelists regarding the overall treatment approach they would use with T-DXd, including its place on the treatment algorithm for HER2-positive, HR-positive/HER2-low, and HR-negative/HER2-low breast cancers (see Table 2). Here, ERBB2 is linked to breast carcinoma.